Efficacy of the combination of irinotecan and bevacizumab in heavely pretreated metastatic breast cancer

12001 Background: The level of angiogenic activity in breast cancer has been shown to be a determinant of disease progression. Adding an antiangiogenic agent to chemotherapy has demonstrated to improve disease free survival and overall survival in patients diagnosed of metastatic breast cancer. We present a retrospective analysis of patients treated at our institution with bevacizumab plus irinotecan based chemotherapy. Methods: Pretreated patients with metastatic breast cancer received bevacizumab in combination with chemotherapy. Toxicity was graded according to the NCI Common Toxicity Criteria and response was evaluated using the RECIST criteria and biochemical parameters. Results: A total of 15 patients diagnosed of metastatic breast cancer were included. The median of age was 55 years. The 93.3% had bone metastases, the 80% showed liver disease, 46.7% had pulmonary metastases and the 6.7% had CNS metastases. They were treated from february 2005 to january 2007. They received a median of 6 cycles (1–2...